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thrombosis were acute coronary syndrome at admission, diabetes, and stent
number/length. Age, extent of coronary disease, renal failure and smoking also
appeared as significant predictors, but less consistently. Premature discontinuation
of dual antiplatelet therapy was also a powerful predictor of stent thrombosis.
Conclusions: Despite numerous possible risk factors, the strongest predic-
tors of stent thrombosis are diabetes, acute coronary syndromes, stent length/
number, and premature discontinuation of dual antiplatelet therapy.
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Objectives: To assess the impact on 6-month post-stenting outcomes of
long-term vitamin K antagonist (VKA) therapy at baseline and of continued
versus discontinued VKA therapy.
Background: Dual antiplatelet therapy (DAT) after stenting is associated with
higher bleeding event rates in patients on long-term VKA therapy at stenting.
Methods: Matched case-control study in patients who underwent stenting
at four centers between July 2003 and October 2006. Matching was on age,
sex, and clinical presentation.
Results: We included 181 patients on VKA therapy at stenting and 181 con-
trols. VKA therapy was continued after stenting in 60% of the cases. The 6-month
major adverse event rate (primary endpoint defined as the association of death,
myocardial infarction, stent thrombosis, major bleeding or stroke) was signifi-
cantly higher in the cases than in the controls (odds ratio [OR], 3.3; 95% confi-
dence interval [95%CI], 1.5-6.9; P<0.01). The cases had higher rates of death
(OR, 3.8; 95%CI, 1.0-14.0; P=0.05) and major bleeding (OR, 5.4; 95%CI, 1.5-
18.9; P<0.01). DAT duration was significantly shorter in the cases left on VKA
therapy but did not differ according to stent type. By multivariable analysis, sig-
nificant predictors of the MAE rate in the cases were GpIIb3a treatment during
stenting (hazard ratio [HR], 7.4; 95%CI, 1.8-29.7; P<0.01) and age (HR per year
1.05; 95%CI, 1.0-1.1; P=0.03). There was a non significant reduction in MAE and
major bleeding for cases at 6 months if VKA therapy were continued in associa-
tion with DAT after stenting (rate of MAE: 8.3 vs. 15.7% for discontinued VKA
therapy, p=0.26, rate of major bleeding 3.8 vs 9.7 p=0.16). 
Conclusions: Long-term VKA therapy at stenting is associated with
increased bleeding events and poor outcomes. Continued VKA therapy with
close INR monitoring and a short DAT duration may be appropriate in
patients on long-term VKA therapy at stenting.
039
Benefit of tailored therapy with high clopidogrel maintenance dose
according to CYP2C19 genotypes in clopidogrel non responders
undergoing coronary stenting for acute coronary syndrome 
Thomas Cuisset [Orateur] (1), Jacques Quilici (1), Pierre E Morange (2),
Jean Louis Bonnet (3), Marie Christine Alessi (2)
(1) AP-HM, CHU La Timone, Cardiologie Interventionnelle, Marseille,
France – (2) AP-HM, CHU LA Timone, Inserm, U626, Laboratoire
d’Hématologie, Marseille, France – (3) AP-HM, CHU La Timone, Car-
diologie, Marseille, France
Objectives and background: Loss-of-Function allele CYP2C19*2 has
been associated with impaired clopidogrel response and worse prognosis in
clopidogrel-treated patients. Benefit of Tailored therapy according to platelet
function test remains unclear and potential effect of genotypes on this benefit
has not been addressed in unstable patients. The present study was designed
to evaluate the benefit of tailored therapy with higher maintenance dose
according to CYP2C19 genotypes in patients identified as non responders
undergoing Percutaneous Coronary Intervention (PCI) for Non ST segment
Elevation Acute Coronary Syndrome (NSTE ACS). 
Methods and results: 346 consecutive patients were enrolled, who
received loading dose of 600 mg, including 86 *2 Carriers (13 homozygotes
and 73 heterozygotes) and 260 *2 Non Carriers. Clopidogrel response,
assessed with Platelet Reactivity Index VASP (PRI VASP), was significantly
affected by genotypes with lower Clopidogrel Response in CYP2C19*2 allele
carriers (p=0.01). Accordingly, the rate of clopidogrel non responders was
higher in CYP2C19*2 allele carriers: 53% vs. 41%, p=0.04. All Clopidogrel
non Responders (n=151), including 105 *2 Non Carriers and 46 *2 Carriers,
received High 150 mg clopidogrel maintenance at discharge to overcome ini-
tial non response. After one month, High Maintenance dose overcame clopi-
dogrel non response in only 44 % of the whole population and significantly
less frequently in *2 Carriers than in Non Carriers, 28% vs. 50%, p=0.01.
Conclusion: Higher Clopidogrel Maintenance dose was able to overcome
Clopidogrel Non Response in less than half of Clopidogrel Non Responders
undergoing PCI for NSTE ACS. The benefit of this tailored Therapy was sig-
nificantly reduced in CYP2C19*2 Carriers. Therefore, these patients might
require alternative strategies with new P2Y12 blockers.
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Objective: To investigate the relationship between fragmented QRS com-
plex (fQRS) and parameters of infarct size (IS) and no reflow assessed by car-
diac magnetic resonance (CMR) in patients with acute myocardial infarction.
Patients and methods: Patients with a fQRS were compared with patients
without fQRS. CMR was performed in 246 consecutive patients within the
week following the AMI. Early and late gadolinium-enhanced images were
examined to assess IS and microvascular obstruction. Left ventricular ejection
fraction (LVEF) and left ventricular volumes were also determined.
Results: 128 (52%) presented a fQRS on the first 12-lead ECG 36 hours
post-AMI. Despite similar demographic, ECG and clinical features, patients
with a fQRS were more likely to be male and had a higher systolic blood pres-
sure on admission. Furthermore, patients with a fQRS had a significantly
lower LVEF, and larger IS than did patients without fQRS as assessed by
CMR. Interestingly, myocardial perfusion abnormalities after infarction deter-
mined by first-pass perfusion images (microvascular obstruction=MO) and
late perfusion images (persistent MO=PMO) were significantly more frequent
in the fQRS group (Table 1). By multivariate logistic regression analysis, only
infarct size (OR=0.456; 95%CI: 1.03-1.07, p=0.001) was an independent pre-
dictor of a fragmented QRS.Kaplan Meier Curves for MAE
© Elsevier Masson SAS. All rights reserved.
 
14 Archives of Cardiovascular Diseases Supplements (2012) 4, 1-29
Table 1: CMR data according to the presence of fQRS. N(%) or median
(25th-75th). 
Conclusions: These findings give further support to the argument that
fQRS is a reliable marker of infarct size and could explain its strong prog-
nostic value after AMI.
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Background. We investigated the relationships between the autonomic
nervous system, as assessed by heart rate variability (HRV) and levels of N-
terminal Pro-B-type Natriuretic Peptide (Nt-proBNP), in the setting of acute
myocardial infarction (MI).
Patients and method. Plasma Nt-proBNP (Elecsys, Roche) was measured
on admission in patients admitted < 24h for acute MI. Patients with chronic
atrial fibrillation or pace maker were excluded. The mean of standard devia-
tion of RR intervals (SDNN), percentage of RR intervals with >50ms variation
(pNN50), square root of mean squared differences of successive RR intervals
(rMSSD), and frequency domain parameters (total power (TP), high frequency
and low frequency power ratio (LF/HF)) were assessed by 24h holter ECG
monitoring at 5 ± 2 days after MI onset.
Results. Among the 1018 patients included, median (IQR) Nt-proBNP
value was 681(159-2432) pmol/L. Patients with highest quartile of Nt-proBNP
were older, were more likely to be women, hypertensive, had higher admis-
sion heart rate, lower LVEF, but were less likely to be smokers. Highest Nt-
proBNP quartile group had lower SDNN, LF/HF and total power but similar
pNN50 and rMSSD levels. Nt-proBNP levels was negatively associated with
TP (r=–0.17, p<0.001), SDNN (r=–0.19, p<0.001), LF/HF (r=–0.37, p<0.001),
and LF (r=–0.29, p<0.001) but not HF (r=–0.043, p=0.172). Multiple regres-
sion analysis showed that plasma propeptide level remains predictive of LF/
HF (B(SE)=–0.065(0.015), p<0.001)), after adjustment for confounding (Beta-
blockers, female, and age). 
Conclusions: Our population-based study suggests the importance of Nt-
proBNP levels to predict decreased HRV after acute MI. Moreover, our results
highlight that high Nt-proBNP levels are associated with a decrease in the
effects of the sympathetic system. Further experimental studies are needed to
explore the impact of such findings.
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Context: Periodontal disease, including bone loss, increases the risk of ath-
erosclerosis through plaque destabilization. Multiple complex coronary lesions
(MCL), defined by stenosis >50%, and at least two of the following: chronic
occlusion, impaired flow, thrombus , irregularity, and ulceration of the lesion,
are associated with multifocal destabilization of atherosclerotic coronary
plaque. We investigated whether significant bone loss could predict the pres-
ence of MCL.
Materials and methods: 150 consecutive patients who initiated outpatient
cardiac rehabilitation between 2007 and 2010 for myocardial infarction <1
month and who underwent coronary angiography were included. Patients
without or simple complex coronary lesions (SCL group) were compared to
patients with MCL. A panoramic dental x-ray was made including bone loss>
50%. 
Results: Over 20% of patients had MCL (32/150), and patients in the SCL and
MCL groups had similar cardiovascular risk factors. However, patients with MCL
were less likely to be women and more likely to have multivessel disease than
were patients in the SCL group (21% vs. 6%, p=0.051, and 88% vs. 46%,
p<0.001). Bone loss> 50% tended to be more frequent in patients with MCL than
in those with SCL (50% vs. 32%, p=0.063). In addition, patients with MCL had a
higher CRP level (CRP> 10 mg/L: 15% vs. 42% p=0.001). In multivariate anal-
ysis, multivessel disease (OR (95% CI): 6.63 (2.09-21.03), and CRP>10 mg/L
(OR (95% CI): 3.98 (1.48-10.69)) were associated with the presence of MCL.
Female sex (OR (95% CI): 0.23 (0.04-1.22) tended to be associated with SCL. In
addition, bone loss> 50% significantly increased the risk of MCL (OR 2.63 (1.03-
6.71) p=0.043)) even after adjustment for other predictors of MCL. 
Conclusion: Bone loss, a simple parameter of periodontal evaluation, cor-
related with complex and multiple coronary lesions, independently of other
known factors associated with MCL, including systemic inflammation.
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Aim: Assess if invasive coronary angiogram (CA) can be replaced by mul-
tislice coronary tomography (MSCT) (64 – /256-row) for the systematic rule
out of coronary vasculopathy in heart transplant patients.
Methods: Electrocardiogram-gated contrast-enhanced MSCT (Philipps, Bril-
liance, 64-row for the first 25 patients and 256-row for the others) was per-
formed 24 hours before annual CA. MSCT parameters, adapted to the patient’s
weight, include 120 kV, 800mAs, 0.625 mm slice thickness, 0.42s/0.27s rotation
time. Coronary segments > 1.5 mm were classified as stenosis (stenosis>50%),
atheroma (stenosis<50%) or normal and blindly compared to CA.
The primary endpoint was the negative predictive value (NPV) of MSCT for
the detection of significant (stenosis>50%) coronary artery disease (CAD). Sec-
ondary endpoints were the comparison of X-Ray (mSv) and iodine contrast agent
(ml) exposures. We plan to present the final results (n=102) at SFC meeting.
Results: 87 patients were prospectively included. Mean age was 52 ± 13 years.
Heart transplantation occurred 6±5 years before inclusion. 1108 (97.8%) segments
No fQRS 
n=118 (n=739)
fQRS 
n=128 
p
LVEF, % 56 (48-62) 49 (39-58) <0.001
EDV index (mL/m2) 135 (105-170) 155 (129-190) <0.001
ESV index (mL/m2) 60 (47-77) 76 (57-104) <0.001
Presence of PMO, n (%) 46 (39) 73 (57) 0.007
Presence of MO, n (%) 71(60) 93 (72) 0.052
Extent of PMO, (%) 1.98 (0.95-4.2) 3.5 (1.7-5.6) 0.018
Extent of MO, (%) 8.55 (3.9-14.7) 12.7 (6-23) 0.022
IS, (%) 16 (9-25) 25 (15-34) <0.001
